Combination checkpoint blockade effective in pre-surgical setting for early-stage lung cancers

(University of Texas M. D. Anderson Cancer Center) Neoadjuvant, or pre-surgical, treatment with nivolumab plus ipilimumab resulted in an overall major pathologic response (MPR) rate of 33 percent of treated patients with early-stage, resectable non-small cell lung cancers, meaning these patients had less than or equal to 10 percent viable tumor remaining at surgery. With these results, the combination immunotherapy met the pre-specified trial efficacy endpoint of the phase II NEOSTAR trial conducted by researchers at The University of Texas MD Anderson Cancer Center.

https://www.eurekalert.org/pub_releases/2019-06/uotm-ccb060119.php

Source: EurekAlert! - Medicine and Health - June 3, 2019 Category: International Medicine & Public Health Source Type: news